BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38377560)

  • 41. Discovery of novel 4-(2-pyrimidinylamino)benzamide derivatives as highly potent and orally available hedgehog signaling pathway inhibitors.
    Xin M; Zhang L; Jin Q; Tang F; Wen J; Gu L; Cheng L; Zhao Y
    Eur J Med Chem; 2016 Mar; 110():115-25. PubMed ID: 26820554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
    Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
    Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Design, synthesis and biological evaluation of novel 4-substituted-3-nitrobenzamide derivatives].
    Zhu QF; Gong YX; Zhong JQ; Liu LF; Li XF; Zhao XY
    Yao Xue Xue Bao; 2014 Aug; 49(8):1143-9. PubMed ID: 25322556
    [TBL] [Abstract][Full Text] [Related]  

  • 44. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo.
    Cai D; Qiu Z; Yao W; Liu Y; Huang H; Liao S; Luo Q; Xie L; Lin Z
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1217-29. PubMed ID: 27107592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities.
    Zhu H; Li W; Shuai W; Liu Y; Yang L; Tan Y; Zheng T; Yao H; Xu J; Zhu Z; Yang DH; Chen ZS; Xu S
    Eur J Med Chem; 2021 Apr; 216():113316. PubMed ID: 33676300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
    Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.
    Assi HH; Paran C; VanderVeen N; Savakus J; Doherty R; Petruzzella E; Hoeschele JD; Appelman H; Raptis L; Mikkelsen T; Lowenstein PR; Castro MG
    J Pharmacol Exp Ther; 2014 Jun; 349(3):458-69. PubMed ID: 24696041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Growth inhibitory effects of the Diruthenium-Ibuprofen compound, [Ru2Cl(Ibp) 4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo.
    Benadiba M; de M Costa I; Santos RL; Serachi FO; de Oliveira Silva D; Colquhoun A
    J Biol Inorg Chem; 2014 Aug; 19(6):1025-35. PubMed ID: 24824561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
    Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
    Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
    Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis and binding mode of interaction of novel small molecule o-hydroxy benzamides as HDAC3-selective inhibitors with promising antitumor effects in 4T1-Luc breast cancer xenograft model.
    Routholla G; Pulya S; Patel T; Adhikari N; Abdul Amin S; Paul M; Bhagavatula S; Biswas S; Jha T; Ghosh B
    Bioorg Chem; 2021 Dec; 117():105446. PubMed ID: 34717237
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents.
    Yoshida M; Hayakawa I; Hayashi N; Agatsuma T; Oda Y; Tanzawa F; Iwasaki S; Koyama K; Furukawa H; Kurakata S; Sugano Y
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3328-32. PubMed ID: 15955697
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas.
    Comes Franchini M; Bonini BF; Camaggi CM; Gentili D; Pession A; Rani M; Strocchi E
    Eur J Med Chem; 2010 May; 45(5):2024-33. PubMed ID: 20129719
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enhanced proliferation inhibition and apoptosis in glioma cells elicited by combination of irinotecan and imatinib.
    Lu J; Hu Y; Qian R; Zhang Y; Yang X; Luo P
    Eur J Pharmacol; 2020 May; 874():173022. PubMed ID: 32084420
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synthesis, crystal structure, and cytotoxic activity of novel cyclic systems in [1,2,4]thiadiazolo[2,3-a]pyridine benzamide derivatives and their copper(II) complexes.
    Adhami F; Safavi M; Ehsani M; Ardestani SK; Emmerling F; Simyari F
    Dalton Trans; 2014 Jun; 43(21):7945-57. PubMed ID: 24715093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
    Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
    Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design, synthesis and biological evaluation of benzamide and phenyltetrazole derivatives with amide and urea linkers as BCRP inhibitors.
    Gujarati NA; Zeng L; Gupta P; Chen ZS; Korlipara VL
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4698-4704. PubMed ID: 28916341
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimization of Benzamide Derivatives as Potent and Orally Active Tubulin Inhibitors Targeting the Colchicine Binding Site.
    Lin S; Du T; Zhang J; Wu D; Tian H; Zhang K; Jiang L; Lu D; Sheng L; Li Y; Ji M; Chen X; Xu H
    J Med Chem; 2022 Dec; 65(24):16372-16391. PubMed ID: 36511661
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors.
    Park SY; Oh YJ; Lho Y; Jeong JH; Liu KH; Song J; Kim SH; Ha E; Seo YH
    Eur J Med Chem; 2018 Jan; 143():390-401. PubMed ID: 29202402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.